4.7 Article

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders

Journal

ANNALS OF NEUROLOGY
Volume 85, Issue 2, Pages 259-271

Publisher

WILEY
DOI: 10.1002/ana.25392

Keywords

-

Funding

  1. NIH National Center for Advancing Translational Sciences [TL1TR001880]
  2. National Institute on Aging [AG010124]
  3. National Institute of Neurological Disorders and Stroke [NS088341, NS053488]

Ask authors/readers for more resources

Objective To use digital histology in a large autopsy cohort of Lewy body disorder (LBD) patients with dementia to test the hypotheses that co-occurring Alzheimer disease (AD) pathology impacts the anatomic distribution of alpha-synuclein (SYN) pathology and that co-occurring neocortical tau pathology in LBDs associates with worse cognitive performance and occurs in a pattern differing from AD. Methods Fifty-five autopsy-confirmed LBD (Parkinson disease with dementia, n = 36; dementia with Lewy bodies, n = 19) patients and 25 AD patients were studied. LBD patients were categorized as having moderate/severe AD copathology (SYN + AD = 20) or little/no AD copathology (SYN-AD = 35). Digital measures of tau, beta-amyloid (A beta), and SYN histopathology in neocortical and subcortical/limbic regions were compared between groups and related to antemortem cognitive testing. Results SYN burden was higher in SYN + AD than SYN-AD in each neocortical region (F-1,F- 54 = 5.6-6.0, p < 0.02) but was equivalent in entorhinal cortex and putamen (F-1,F- 43-49 = 0.7-1.7, p > 0.2). SYN + AD performed worse than SYN-AD on a temporal lobe-mediated naming task (t(27) = 2.1, p = 0.04). Antemortem cognitive test scores inversely correlated with tau burden (r = -0.39 to -0.68, p < 0.05). AD had higher tau than SYN + AD in all regions (F-1,F- 43 = 12.8-97.2, p < 0.001); however, SYN + AD had a greater proportion of tau in the temporal neocortex than AD (t(41) = 2.0, p < 0.05), whereas AD had a greater proportion of tau in the frontal neocortex than SYN + AD (t(41) = 3.3, p < 0.002). SYN + AD had similar severity and distribution of neocortical A beta compared to AD (F-1,F- 40-43 = 1.6-2.0, p > 0.1). Interpretation LBD patients with AD copathology harbor greater neocortical SYN pathology. Regional tau pathology relates to cognitive performance in LBD dementia, and its distribution may diverge from pure AD. Tau copathology contributes uniquely to the heterogeneity of cognitive impairment in LBD. Ann Neurol 2018; 1-13 ANN NEUROL 2019;85:259-271.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Clinical Neurology

Concomitant Alzheimer Disease Pathology in Parkinson Disease Dementia

Thomas F. Tropea, Isabela Albuja, Katheryn A. Q. Cousins, David J. Irwin, Edward B. Lee, Alice S. Chen-Plotkin

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies

Alexandra L. Young, Jacob W. Vogel, John L. Robinson, Corey T. McMillan, Rik Ossenkoppele, David A. Wolk, David J. Irwin, Lauren Elman, Murray Grossman, Virginia M. Y. Lee, Edward B. Lee, Oskar Hansson

Summary: Through data-driven disease progression modelling, a fine-grained empirical staging system for TAR DNA-binding protein-43 (TDP-43) proteinopathies has been established, which can accurately classify frontotemporal lobar degeneration due to TDP-43 (FTLD-TDP), amyotrophic lateral sclerosis (ALS) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). The study reveals substantial heterogeneity in the progression patterns of ALS and FTLD-TDP, and highlights the need for further investigation in larger cross-cohort studies.

BRAIN (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.

BRAIN (2023)

Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Review Clinical Neurology

Fluid and Biopsy Based Biomarkers in Parkinson's Disease

David G. Coughlin, David J. Irwin

Summary: Several advances have been made in fluid and tissue-based biomarkers for Parkinson's disease (PD) and other synucleinopathies in the last few years. Immunohistochemistry, immunofluorescence, and alpha-synuclein seeding amplification assays now offer a crucial advancement in identifying different species of alpha-synuclein in PD patients. Co-pathology of Alzheimer's disease (AD) is commonly found in PD and dementia with Lewy bodies (DLB), and biofluid biomarkers for tau and amyloid beta species can detect this co-pathology.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Review Medical Laboratory Technology

Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology

Ju Hee Kang, Magdalena Korecka, Edward B. Lee, Katheryn A. Q. Cousins, Thomas F. Tropea, Alice A. Chen-Plotkin, David J. Irwin, David Wolk, Magdalena Brylska, Yang Wan, Leslie M. Shaw

Summary: Development of validated biomarkers for early detection of Alzheimer's disease neuropathology is crucial for therapeutic trials. Although CSF and neuroimaging biomarkers have limitations, there is a growing focus on accelerating the development of blood-based AD biomarkers. The use of the AT(N) classification by CSF and imaging biomarkers provides a more objective diagnosis of AD. Blood-based AD biomarkers can be utilized as screening tools in therapeutic trials and clinical care.

CLINICAL CHEMISTRY (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Antemortem network analysis of spreading pathology in autopsy-confirmed frontotemporal degeneration

Min Chen, Sarah Burke, Christopher A. Olm, David J. Irwin, Lauren Massimo, Edward B. Lee, John Q. Trojanowski, James C. Gee, Murray Grossman

Summary: Chen et al. used graph-theoretic analyses of antemortem, multimodal MRIs to examine spreading pathology in structural networks of those with autopsy-confirmed frontotemporal lobar degeneration with either tau or transactional DNA binding protein of similar to 43 kDa inclusions. They report distinct patterns of long-range and short-range network degradation between the two pathologies, suggesting different mechanisms for their spread.

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

Digital markers of motor speech impairments in spontaneous speech of patients with ALS-FTD spectrum disorders

Sanjana Shellikeri, Sunghye Cho, Sharon Ash, Carmen Gonzalez-Recober, Corey T. Mcmillan, Lauren Elman, Colin Quinn, Defne A. Amado, Michael Baer, David J. Irwin, Lauren Massimo, Christopher A. Olm, Mark Y. Liberman, Murray Grossman, Naomi Nevler

Summary: This study evaluated the effectiveness of automated digital speech measures in assessing bulbar motor impairments in patients with ALS-FTD spectrum disorders. The results showed that vowel measures derived from spontaneous speech were able to effectively assess bulbar dysfunction, with greater sensitivity and specificity compared to traditional assessments such as speaking rate.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)

Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo

MOVEMENT DISORDERS (2023)

No Data Available